CD276 as a critical independent biomarker and immune checkpoint inhibitor target in epithelioid mesothelioma-TCGA study.

• Tác giả: Yuko Aoki, Ken Arimura, Kenzo Hiroshima, Mitsuko Kondo, Yasuto Sato, Etsuko Tagaya
• Ngôn ngữ: eng
• Ký hiệu phân loại: 332.7 Credit
• Thông tin xuất bản: China : Journal of thoracic disease , 2025
• Bộ sưu tập: NCBI
• ID: 471940

Tóm tắt

BACKGROUND: CD276 is an immune checkpoint, and immune checkpoint inhibitors (ICIs) targeting CD276 have been tested against various cancers. However, the precise role of CD276 in mesothelioma subtypes is unknown. This study aimed to reveal the prognostic significance of CD276 in various cancers and explore CD276 as a target for ICIs in different mesothelioma subtypes. METHODS: We evaluated data from The Cancer Genome Atlas (TCGA) database retrospectively. The Wilcoxon rank-sum test was used to assess RESULTS: Upregulated CONCLUSIONS: CD276 is an independent prognostic biomarker in patients with epithelioid mesothelioma. It is associated with the glycolytic pathway and may contribute to ATP generation in epithelioid mesothelioma. CD276 inhibitors might contribute to better prognosis in patients with epithelioid mesothelioma.